← Azimuth Daily
Capturing data…
Capturing data…
SUN, 25 OCT · 77 ITEMS
"FDA approves AstraZeneca drug for rare kidney disease in adults" — Reuters (Reuters.com) · Science & Medicine
The US FDA granted to AstraZeneca's Ultomiris (ravulizumab) for reducing in adults with primary immunoglobulin A nephropathy (IgAN), a rare autoimmune kidney disease that can lead to kidney failure. This is the first approved for IgAN, and it targets the underlying disease mechanism rather than just symptoms.
The claim is solid, based on an FDA announcement and an AstraZeneca press release, both primary sources. Reuters, a reputable secondary source, reports the news accurately; the accelerated approval is confirmed across multiple outlets including the FDA's own website and the company's release.
Genuinely new: the FDA approval was announced on October 21, 2026, and the news broke the same day.
We previously covered the FDA approval of a Vera Therapeutics treatment for immunoglobulin A nephropathy in July 2026, another new drug for the same rare disease.